{"id":4547,"date":"2025-06-30T16:57:39","date_gmt":"2025-06-30T11:27:39","guid":{"rendered":"https:\/\/www.eqwires.com\/tutorials\/?p=4547"},"modified":"2025-06-30T16:57:40","modified_gmt":"2025-06-30T11:27:40","slug":"motilal-oswal-reiterates-neutral-view-on-torrent-pharma-despite-jb-chemicals-buyout-plans","status":"publish","type":"post","link":"https:\/\/www.eqwires.com\/tutorials\/motilal-oswal-reiterates-neutral-view-on-torrent-pharma-despite-jb-chemicals-buyout-plans\/","title":{"rendered":"Motilal Oswal Reiterates \u2018Neutral\u2019 View on Torrent Pharma Despite JB Chemicals Buyout Plans"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\" id=\"0\">Motilal Oswal has maintained its <strong>\u201cNeutral\u201d rating<\/strong> on <strong>Torrent Pharmaceuticals<\/strong>, setting a price target of <strong>\u20b93,430<\/strong>, which implies modest upside of around <strong>3%<\/strong> from current levels. The brokerage\u2019s stance reflects both the <strong>strategic potential<\/strong> and <strong>execution risks<\/strong> linked to Torrent\u2019s ambitious plan to acquire <strong>JB Chemicals &amp; Pharmaceuticals (JBCP)<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Here\u2019s a closer look at what\u2019s driving this cautious optimism:<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Portfolio Expansion Brings Growth\u2014and Challenges<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The acquisition would give Torrent access to JBCP\u2019s <strong>fast-growing domestic formulation business<\/strong>, which includes a strong chronic care portfolio.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Torrent plans to purchase up to <strong>46.4% stake<\/strong> in JBCP for \u20b911,900 crore (<strong>\u20b91,600 per share<\/strong>) and will also launch a <strong>mandatory open offer<\/strong> for an additional <strong>26%<\/strong> stake.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Post-merger, JBCP\u2019s <strong>\u20b92,300 crore domestic sales<\/strong> and <strong>2,800+ field force<\/strong> will integrate into Torrent\u2019s existing <strong>\u20b96,400 crore India business<\/strong>, creating potential synergies across therapies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">However, Motilal Oswal cautioned that successful <strong>integration<\/strong> and a clear strategy for <strong>cross-selling<\/strong> will be critical to unlock value from the combined entity.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Valuation: Strategic Sense, But No Bargain<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Motilal Oswal noted that while the deal is consistent with Torrent\u2019s expansion goals, the valuation is not exactly cheap.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Torrent is paying:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>30.7\u00d7 FY26E earnings (27\u00d7 FY27E)<\/strong><\/li>\n\n\n\n<li><strong>22\u00d7 FY26E EBITDA<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These multiples are <strong>lower than Torrent\u2019s own 47\u00d7 FY26 earnings<\/strong>, but still <strong>significantly above sector averages<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In the brokerage\u2019s words:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">\u201cValuation supports strategic rationale, but does not leave much room for re-rating.\u201d<\/p>\n<\/blockquote>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Funding Mix Could Pressure Near-Term Earnings<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Torrent already carries about <strong>\u20b92,250 crore of net debt<\/strong>. If the acquisition is funded entirely through borrowing, Motilal Oswal estimates an <strong>earnings dilution of around 10.5% in FY27<\/strong> due to higher interest costs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Outside of the JBCP deal, Torrent is expected to deliver a healthy growth trajectory with:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>12% revenue CAGR<\/strong><\/li>\n\n\n\n<li><strong>14% EBITDA CAGR<\/strong><\/li>\n\n\n\n<li><strong>23% PAT CAGR over FY25\u2013FY27<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Motilal Oswal continues to value Torrent at <strong>38\u00d7 12-month forward earnings<\/strong>, supporting the <strong>\u20b93,430 target price<\/strong>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Bottom Line<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">While the acquisition could strengthen Torrent\u2019s presence in chronic therapies and expand its domestic portfolio meaningfully, the brokerage believes the <strong>limited upside from current levels warrants a Neutral stance<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"0\">For investors, the big question will be how effectively Torrent manages integration and balances funding to avoid a drag on profitability.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"0\"><strong><a href=\"https:\/\/www.eqwires.com\/tutorials\/who-is-the-best-sebi-registered-investment-advisor-in-i\">Eqwires Research Analyst<\/a><\/strong><\/p>\n\n\n\n<p class=\"has-dark-gray-color has-text-color wp-block-paragraph\"><strong><a href=\"https:\/\/www.eqwires.com\/\">Top-notch SEBI registered research analyst<\/a><\/strong><\/p>\n\n\n\n<p class=\"has-dark-gray-color has-text-color wp-block-paragraph\"><strong><a rel=\"noreferrer noopener\" href=\"https:\/\/www.eqwires.com\/\" target=\"_blank\">Best SEBI registered Intraday tips provider <\/a><\/strong><\/p>\n\n\n\n<p class=\"has-dark-gray-color has-text-color wp-block-paragraph\"><a href=\"mailto:info@eqwires.com\"><strong>info@eqwires.com<\/strong><\/a><\/p>\n\n\n\n<p class=\"has-dark-red-color has-text-color wp-block-paragraph\"><strong><a href=\"https:\/\/t.me\/eqwires\">Telegram&nbsp;<\/a>|&nbsp;<a href=\"https:\/\/www.facebook.com\/eqwires\/\">Facebook&nbsp;<\/a>|&nbsp;<a href=\"https:\/\/instagram.com\/Eqwires\">Instagram<\/a><\/strong><\/p>\n\n\n\n<p class=\"has-dark-red-color has-text-color wp-block-paragraph\"><strong>Call: +91 9624421555 \/&nbsp;<em>+91 9624461555<\/em><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><a href=\"http:\/\/www.eqwires.com\/\">www.eqwires.com<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Motilal Oswal has maintained its \u201cNeutral\u201d rating on Torrent Pharmaceuticals, setting a price target of \u20b93,430, which implies modest upside of around 3% from current levels. The brokerage\u2019s stance reflects both the strategic potential and execution risks linked to Torrent\u2019s ambitious plan to acquire JB Chemicals &amp; Pharmaceuticals (JBCP). Here\u2019s a closer look at what\u2019s driving this cautious optimism: Portfolio Expansion Brings Growth\u2014and Challenges The acquisition would give Torrent access to JBCP\u2019s fast-growing domestic formulation &hellip; <a href=\"https:\/\/www.eqwires.com\/tutorials\/motilal-oswal-reiterates-neutral-view-on-torrent-pharma-despite-jb-chemicals-buyout-plans\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Motilal Oswal Reiterates \u2018Neutral\u2019 View on Torrent Pharma Despite JB Chemicals Buyout Plans&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":4548,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[74],"tags":[],"class_list":["post-4547","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-sebi-registered-advisory-company"],"_links":{"self":[{"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/posts\/4547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/comments?post=4547"}],"version-history":[{"count":1,"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/posts\/4547\/revisions"}],"predecessor-version":[{"id":4549,"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/posts\/4547\/revisions\/4549"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/media\/4548"}],"wp:attachment":[{"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/media?parent=4547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/categories?post=4547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/tags?post=4547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}